Information about the use of antiretroviral drugs in pregnancy and other aspects of care for HIV-positive women during pregnancy, so as to prevent vertical transmission and ensure the best outcomes for both mother and infant.

Prevention of mother-to-child transmission: latest news

Prevention of mother-to-child transmission resources

Prevention of mother-to-child transmission features

Prevention of mother-to-child transmission in your own words

Prevention of mother-to-child transmission news from aidsmap

More news

Prevention of mother-to-child transmission news selected from other sources

  • Malaysia eliminates HIV transmission from mother-to-child

    Malaysia celebrates milestone victory for preventable diseases in babies.

    05 November 2018 | AVERT
  • Nigeria highest producer of HIV-infected babies

    The Federal Government has confirmed a report, which ranks Nigeria first on the list of countries with high record of mother-to-child transmission of HIV/AIDS in the world.

    05 November 2018 | Daily Post
  • Uganda: Mother-to-child HIV infections drop by 86%

    Mother-to-child HIV infections in Uganda have fallen to an all-time low of 4,000 in 2017, from 25,000 in 2011, First Lady and Education minister Janet Museveni has said.

    23 October 2018 | The Observer
  • Dolutegravir Use During Pregnancy: What Are the Risks?

    Infectious Disease Advisor spoke to Rebecca M. Zash, MD, a co-investigator of the interim analysis by the Tsepamo Study in Botswana, which was published in the New England Journal of Medicine in July.

    22 October 2018 | Infectious Disease Advisor
  • What you need to know about SA's historic liver transplant from an HIV-positive donor

    How could a baby get an organ from a person living with HIV and not automatically contract the virus? The experts weigh in.

    09 October 2018 | Bhekisisa
  • HIV stigma blocks efforts to prevent mother-to-child transmission in India

    Outreach workers identify a number of personal, social, and structural challenges that impede efforts to prevent mother-to-child transmission of HIV in India.

    05 October 2018 | AVERT
  • AIDS 2018: The Story is Messy

    It's already clear that the story from Amsterdam is that ending epidemic levels of new HIV diagnoses depends on building services and societies that recognize individuals as wonderful, wild, weird, whole people, with more specificity, respect and rigor than ever before. It also depends on activism, nasty women and their male allies, everyone demanding change, refusing to play nice.

    26 July 2018 | AVAC
  • Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

    New pharmacokinetic data show mean exposure of darunavir (brand name Prezista) boosted with cobicistat (available in combination in Rezolsta, Symtuza) to be lower during the second and third trimesters of pregnancy than during 6–12 weeks postpartum. Low darunavir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child.

    18 July 2018 | MHRA
  • Dolutegravir preconception signal: time is up for shoddy surveillance

    The news in May 2018 of a potential risk of neural tube defects in infants born to women taking dolutegravir (DTG) at the time of conception sent shockwaves through the HIV community. But, despite massive global investment, aggressive transition plans – as well as calls for years for more systematic recording of outcomes when women receive ART in pregnancy– few prospective birth registrieshave been established in other settings that can refute or confirm this finding. Meanwhile, women of child-bearing age, whether they intend to become pregnant or not, are being told that they must stick with (or go back to) efavirenz (EFV) – a drug that, before this news, was in the process of being replaced with DTG.

    16 July 2018 | HIV i-Base
  • Dolutegravir: need to consider all pros and cons before switching in pregnancy

    A young pregnant woman who switched from dolutegravir (DTG)-based ART, in response to the neural tube defect safety signal, experienced viral rebound on her new regimen. She needed to be switched back to DTG to achieve re-suppression and prevent vertical transmission.

    11 July 2018 | HIV i-Base
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.